Johnson & Johnson (JNJ)
Stock Of The Day: Johnson & Johnson Hits Crucial Roadblock — Can It Break Through?
Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level.
Johnson & Johnson Q2: Robust New Product Pipeline
Johnson & Johnson beats market estimates for revenue and EPS in Q2 FY24. A strong product pipeline includes new drugs for ulcerative colitis and lung cancer. JNJ's acquisition of Shockwave Medical positions the company as a leader in the cardiovascular market, potential revenue synergies from integration.
5 Deep Value Stocks To Buy in July
Warren Buffett champions value investing, focusing on undervalued companies with strong fundamentals for long-term growth and stability.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript
Johnson & Johnson (NYSE:JNJ ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Joaquin Duato - Chairman and Chief Executive Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Rick Wise - Stifel Terence Flynn - Morgan Stanley Josh Jennings - TD Cowen Dave Risinger - Leerink Partners Danielle Antalffy - UBS Chris Shibutani - Goldman Sachs Joanne Wuensch - Citibank Operator Good morning, and welcome to Johnson & Johnson's Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson climbs after earnings and revenue beat
Johnson & Johnson (NYSE:JNJ) shares climbed 3% after second-quarter earnings fell less than expected. Helped by 8% sales from its pharmaceutical arm, group revenue rose 4.3% to $22.45 billion, which was above the $22.3 billion Wall Street average forecast.
This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum
Johnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings release is that organic growth is back in the picture.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance
Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago.
Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs
On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.
Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed
Shares of Johnson & Johnson JNJ, +1.19% rose 1.1% in premarket trading Wednesday, after the drug maker beat second-quarter profit and sales expectations, while providing a mixed full-year outlook. Net income fell to $4.69 billion, or $1.93 a share, from $5.14 billion, or $2.05 a share, in the same period a year ago.
